[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cabg\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cabg":31},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,29,0,25,[9,50,85,111,135,161,190,218,260,298,325,349,370,397,420,445,468,495,532,554,583,604,626,645,669],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100652570","the-impact-of-left-stellate-ganglion-block-on-systemic-inflammation-and-neuromodulation-in-cabg-surgery-100652570",false,"NCT07776496","The Impact of Left Stellate Ganglion Block on Systemic Inflammation and Neuromodulation in CABG Surgery.","The Impact of Left Stellate Ganglion Block on Systemic Inflammation and Neuromodulation in CABG Surgery","Inclusion Criteria:\n\n1. All elderly (≥65 years) patients of both genders, as according to the World Health Organization, the chronologic age of 65 years was accepted by most developed countries in the world as a definition of \"elderly\" or older person. Patients scheduled for elective cardiac surgery under general anesthesia.14\n2. American Society of Anesthesiologists (ASA) physical status class II or III.\n3. Patients will be stratified according to their baseline surgical risk utilizing the EuroSCORE II tool \\>4%15.\n4. American Society of Anesthesiologists (ASA) physical status class II or III.\n\nExclusion Criteria:\n\n1. Pre-existing dementia or significant cognitive impairment.\n2. History of stroke or cerebrovascular disease.\n3. Contraindications to SGB (e.g., coagulopathy, local infection, or anatomical abnormalities).\n4. Preoperative use of antipsychotics or antidepressants.\n5. Sinus bradycardia \\\u003C50bpm \\&complete heart block\n6. BMI\\>35\n7. Redo or emergency surgery.\n8. On preoperative mechanical ventilation and long sedation time.\n9. Low EF patients \\\u003C35%.","ALL","65 Years","85 Years",{"count":21,"type":22},81,"ESTIMATED","INTERVENTIONAL",[25],"NA","((82)) patients scheduled to undergo elective CABG by the same surgical team will be allocated randomly by computer-generated random numbers into two equal groups (n= 41).\n\nStudy groups:\n\nGroup S (Stellate Ganglion Block Group):\n\nPatients will receive an ultrasound-guided Left stellate ganglion block prior to induction of general anesthesia. The block will be performed at the C6 level under strict aseptic precautions using 5 mL of 0.25% bupivacaine. Successful blockade will be confirmed by the appearance of ipsilateral Horner's syndrome.\n\nGroup C (Control Group):\n\nPatients will receive standard perioperative care without stellate ganglion block and will undergo the same anesthetic and surgical management protocol as Group S.",[28,29,30,31],"Delirium - Postoperative","Inflammation Biomarkers","Stellate Ganglion Block","CABG",[33,34,35,36,37],"postoperative Delirium","stellate ganglion block","SGB","IL6","Inflammatory biomarkers","NOT_YET_RECRUITING","2026-08-17",{"date":41,"type":42},"2026-08-20","ACTUAL",{"date":44,"type":22},"2026-12-01",{"date":46,"type":22},"2028-08-01",{"name":48,"class":49},"OMAR ABDELAZIZ ABOELFADL","OTHER",{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100649218","early-postoperative-physiotherapy-to-prevent-respiratory-insufficiency-after-elective-heart-surgery-100649218","NCT07730034","Early Postoperative Physiotherapy to Prevent Respiratory Insufficiency After Elective Heart Surgery","Early Postoperative Physiotherapy in the Prevention Respiratory Insufficiency After Elective Heart Surgery","EPP-CABG","Inclusion Criteria:\n\n* Adults aged 18-80 years\n* Male and female participants\n* Elective coronary artery bypass grafting (CABG)\n* Body mass index (BMI) \\\u003C 30 kg\u002Fm²\n* Left ventricular ejection fraction (EF) \\> 25%\n* Extubated on postoperative day 0 (POD 0)\n* Able and willing to provide written informed consent\n* Able to perform spirometry and follow study instructions\n\nExclusion Criteria:\n\n* Refusal or inability to provide informed consent\n* Emergency CABG surgery\n* Previous cardiac surgery\n* Severe cardiac arrhythmias (e.g., ventricular tachycardia\u002Ffibrillation, third-degree atrioventricular block)\n* Previous stroke\n* Motor impairment of upper or lower extremities due to neurological or musculoskeletal disease\n* Dyskinesia\n* Not extubated on POD 0\n* Significant postoperative neurological complications\n* Peripheral arterial disease of the lower extremities or previous lower-limb amputation\n* Acute or chronic pulmonary disease\n* Preoperative FEV1 \\\u003C30% of predicted (greater than 70% reduction)\n* Inability to perform spirometry correctly\n* Cancelled surgery after preoperative assessment\n* Extubation later than 24 hours after surgery\n* Requirement for continuous positive airway pressure (CPAP) after extubation SpO₂ \\\u003C90% one hour after extubation despite oxygen supplementation (4 L\u002Fmin by nasal cannula)\n* Return to the operating room after the initial CABG procedure\n* Requirement for dialysis (acute or chronic)","18 Years","80 Years",{"count":61,"type":22},40,[25],"This study aims to determine whether starting respiratory physiotherapy one hour after removal of the breathing tube following elective coronary artery bypass graft (CABG) surgery leads to better recovery than the current standard approach, in which physiotherapy begins on the first postoperative day. The study will evaluate whether earlier physiotherapy improves lung function, reduces postoperative pulmonary complications, shortens intensive care unit and hospital stay, decreases pain and anxiety, and improves overall recovery after surgery. The main question is whether very early postoperative respiratory physiotherapy provides additional benefits for patients recovering from elective heart surgery compared with standard postoperative care.",[31,65,66],"Respiratory Insufficiency","Postoperative Pulmonary Complications (PPCs)",[68,69,70,71,72,73],"Coronary artery bypass grafting (CABG)","Early postoperative physiotherapy","Respiratory physiotherapy","Cardiac surgery","Pulmonary rehabilitation","Respiratory insufficiency","RECRUITING","2026-08-11",{"date":77,"type":42},"2026-08-12",{"date":79,"type":42},"2026-08-04",{"date":81,"type":22},"2027-06",{"name":83,"class":49},"Dijana Filipović",1,{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":95,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":84},"100650233","nonintubated-anesthesia-for-adult-cardiac-surgery-with-cardiopulmonary-bypass-100650233","NCT07744009","Nonintubated Anesthesia for Adult Cardiac Surgery With Cardiopulmonary Bypass","Nonintubated Supraglottic Airway Anesthesia With Early Restoration of Spontaneous Breathing Versus Conventional Endotracheal Fast-Track Anesthesia in Adults Undergoing Cardiac Surgery With Cardiopulmonary Bypass: A Multicenter Randomized Clinical Trial","NIA-Heart","Inclusion Criteria:\n\n* Age 18 years or older, regardless of sex\n* Scheduled to undergo elective cardiac valve surgery with cardiopulmonary bypass\n* Considered eligible for either the non-intubated supraglottic airway anesthesia with early restoration of spontaneous breathing (NIA) strategy or the conventional anesthesia strategy, based on a joint preoperative assessment by the anesthesiology and cardiac surgery teams\n* Relatively stable vital signs and able to complete the required perioperative assessments and follow-up\n* Willing to participate in the study and able to provide written informed consent personally or through a legally authorized representative\n\nExclusion Criteria:\n\n* Emergency or urgent cardiac surgery\n* Severe pulmonary infection, severe respiratory failure, or another preoperative condition that clearly precludes use of the NIA strategy\n* Severe preoperative hemodynamic instability requiring high-dose vasoactive medications or mechanical circulatory support\n* Known difficult airway, high risk of aspiration, or another anesthetic contraindication to the NIA strategy\n* Severe hepatic, renal, or neurological disease that may substantially affect the assessment of perioperative outcomes\n* Pregnant or breastfeeding\n* Previous or concurrent participation in another interventional clinical trial that may affect the results of this study, if the participant remains within the relevant intervention or carryover period\n* Any other protocol-specified clinical condition that, in the opinion of the investigator, makes the participant unsuitable for enrollment",{"count":94,"type":22},300,[25],"The goal of this prospective, multicenter, randomized clinical trial is to learn whether a nonintubated supraglottic airway anesthesia strategy with early restoration of spontaneous breathing can reduce postoperative pulmonary complications and improve early recovery in adults undergoing elective cardiac surgery with cardiopulmonary bypass.\n\nThe main questions it aims to answer are whether, compared with conventional endotracheal fast-track anesthesia, the nonintubated strategy can reduce pulmonary complications within 30 days after surgery, reduce the need for postoperative invasive mechanical ventilation and other respiratory support, and shorten the time spent in the intensive care unit.\n\nParticipants will be randomly assigned to undergo cardiac surgery using either a standardized nonintubated supraglottic airway anesthesia strategy with early restoration of spontaneous breathing or a conventional endotracheal fast-track anesthesia strategy. Both groups will receive standardized perioperative care, with objective criteria for airway removal and readiness for discharge from the intensive care unit. Endotracheal intubation or escalation of respiratory and circulatory support will be performed whenever clinically necessary.\n\nParticipants will be followed from screening through hospitalization, at 30 days after surgery, and for up to 1 year. Routine perioperative data and key postoperative outcomes, including pulmonary complications, respiratory support, intensive care unit stay, major organ complications, safety events, recovery, rehospitalization, and survival, will be collected.",[98,31],"Valve Disease, Heart",[100,101],"Enhanced recovery after surgert","cardiac surgery","2026-08-06",{"date":104,"type":42},"2026-08-07",{"date":106,"type":42},"2026-07-21",{"date":108,"type":22},"2028-12-31",{"name":110,"class":49},"The First Affiliated Hospital of Guangzhou Medical University",{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":122,"conditions":123,"keywords":124,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":131,"leadSponsor":133,"locationsCount":84},"100648743","structured-inpatient-physiotherapy-in-high-risk-coronary-artery-bypass-grafting-patients-100648743","NCT07725887","Structured Inpatient Physiotherapy in High-Risk Coronary Artery Bypass Grafting Patients","Effect of a Preoperatively Initiated Structured Inpatient Physiotherapy Program on Postoperative Outcomes in High-Risk Coronary Artery Bypass Grafting Patients","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Scheduled to undergo elective coronary artery bypass grafting (CABG).\n* High-risk patients meeting at least three of the following criteria:\n\nLeft ventricular ejection fraction (LVEF) \\\u003C40%. Three-vessel coronary artery disease. More than two comorbidities. History of smoking. Age \\>65 years.\n\n\\- Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Planned redo CABG surgery.\n* Severe neurological or orthopedic conditions limiting mobilization.\n* Severe cognitive impairment.\n* Hemodynamic instability.\n* Contraindications to mobilization or exercise.\n* Inability to complete at least two days of the preoperative physiotherapy program.","90 Years",{"count":120,"type":22},100,[25],"Coronary artery bypass grafting (CABG) may be associated with prolonged recovery, particularly in high-risk patients. Although preoperative rehabilitation has shown promising results, evidence remains limited because of heterogeneous intervention protocols and variations in postoperative care. This study aims to investigate the effects of a structured inpatient physiotherapy program initiated at least two days before surgery and continued postoperatively, compared with the same structured physiotherapy program provided only during the postoperative period, in high-risk CABG patients. The primary outcome is hospital length of stay. Secondary outcomes include intensive care unit length of stay, C-reactive protein, neutrophil-to-lymphocyte ratio, hemoglobin, dyspnea, and fatigue.",[31],[31,125,126],"preoperative rehabilitation","postoperative rehabilitation","2026-07-22",{"date":129,"type":42},"2026-07-24",{"date":127,"type":42},{"date":132,"type":22},"2027-01-03",{"name":134,"class":49},"Bezmialem Vakif University",{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":141,"targetDuration":4,"studyType":23,"phases":143,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":160},"100643471","impact-of-del-nido-versus-blood-cardioplegia-on-myocardial-viability-assessed-with-magnetic-resonance-imaging-100643471","NCT07637266","Impact of Del Nido Versus Blood Cardioplegia on Myocardial Viability Assessed With Magnetic Resonance Imaging","Eligibility Criteria:\n\n1\\. Patients with multivessel coronary artery disease scheduled for elective coronary artery bypass grafting\n\nExclusion Criteria:\n\n1. Left ventricular ejection fraction \\\u003C30%\n2. Associated cardiac procedures\n3. Off-pump coronary artery bypass grafting\n4. Contraindications for MRI\n5. Inability to provide consent",{"count":142,"type":22},60,[25],"Myocardial protection during surgical myocardial revascularization is crucial for reducing perioperative myocardial injury and improving postoperative outcomes. Blood cardioplegia represents the standard method in many centers, while del Nido cardioplegia, originally developed for the pediatric population, is increasingly being used in adult patients as well.",[31,146],"Myocardial Viability",[31,148,149,150],"Cardiac magnetic resonance imaging","Coronary artery disease","cardioplegia","2026-06-07",{"date":153,"type":42},"2026-06-09",{"date":155,"type":42},"2026-06-01",{"date":157,"type":22},"2027-06-01",{"name":159,"class":49},"Klinički Bolnički Centar Zagreb",2,{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":23,"phases":170,"briefSummary":171,"conditions":172,"keywords":175,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":160},"100638546","low-dose-interleukin-2-after-myocardial-infarction-to-investigate-effects-on-tissue-resident-regulatory-t-cells-100638546","NCT07610538","Low-dose Interleukin-2 After Myocardial Infarction to Investigate Effects on Tissue-resident Regulatory T Cells","Leuk-ALIVE","Inclusion Criteria:\n\n* Aged over 18 years old\n* Undergoing CABG surgery\n\nExclusion Criteria:\n\n* Critical left main stem coronary disease\n* Severe valvular disease (for example 'severe' aortic stenosis as classified on echocardiogram report)\n* Haemodynamic instability caused by arrhythmia requiring cardioversion in the current admission\n* Non-sustained ventricular tachycardia of \\>10 beats in the last 48 hours\n* Autoimmune disease\n* Any regular immunosuppressive treatment \\[Inhaled or topical steroids are permissible\\]\n* Known active hepatic disease or alanine aminotransferase (ALT) \\> 3xULN\n* Severe chronic kidney disease (defined as eGFR \\\u003C 30 ml\u002Fmin\u002F1.73m2)\n* Allergy or intolerance to aldesleukin\n* Signs and symptoms of active infection\n* History of human immunodeficiency virus (HIV), hepatitis B or C\n* Current malignancy requiring active treatment\n* Vaccine within 4 weeks prior to screening\n* Women of child-bearing potential and pregnancy (women must be either postmenopausal (defined as being amenorrhoeic for greater than 2 years with an appropriate clinical profile (e.g. age appropriate (\\>55 years old), history of vasomotor symptoms) or having documented hysterectomy and\u002For bilateral oophorectomy)\n* Women who are breast-feeding\n* Clinically relevant medical or surgical conditions that, in the opinion of the investigator, would put the subject at risk by participating in the study",{"count":169,"type":22},24,[25],"The primary goals of this study are to compare the differences in tissue-resident Treg gene signature for activation, proliferation, and suppressive function using single-cell\u002F-nucleus RNA sequencing in patients treated with ld-IL-2 compared to control grouped by individual tissue beds from in and around the heart. Additionally, tissue-resident Tregs will be compared to peripheral blood Tregs from the same patient to assess the differential effect of ld-IL-2 on the two compartments.",[173,174,31],"Coronary Artery Disease","Myocardial Infarction (MI)",[176,177,178,179,31,180],"Interleukin-2","IL-2","MI","Myocardial infarction","Coronary artery bypass graft","2026-05-20",{"date":183,"type":42},"2026-05-28",{"date":185,"type":42},"2026-03-31",{"date":187,"type":22},"2028-12-01",{"name":189,"class":49},"Cambridge University Hospitals NHS Foundation Trust",{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":23,"phases":199,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":4},"100622105","soft-foam-dressings-for-pressure-injury-prevention-of-cardiac-surgery-100622105","NCT07379294","Soft Foam Dressings for Pressure Injury Prevention of Cardiac Surgery","Effectiveness of Using Soft Foam Dressings in Preventing Pressure Injuries During Cardiac Surger","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Scheduled to undergo cardiac surgery under general anesthesia\n* Use of cardiopulmonary bypass (CPB) during surgery\n* Expected surgical duration greater than 4 hours\n* Intact skin without pre-existing pressure injury prior to surgery\n\nExclusion Criteria:\n\n* Surgical position other than supine\n* Long-term bedridden status prior to hospital admission\n* Altered consciousness or inability to cooperate\n* History of stroke with residual limb weakness",{"count":198,"type":22},80,[25],"The purpose of this study is to evaluate whether the application of soft foam dressings can reduce the occurrence of surgery-related pressure injuries among patients undergoing cardiac surgery. Specifically, this research aims to investigate differences in pressure injury outcomes before and after the intervention, and to assess the preventive effectiveness of soft foam dressings as an adjunctive skin-protection strategy.",[202,31,98,203,204,205,206,207,208],"CAD - Coronary Artery Disease","Aortic Diseases","Valve Heart Stenosis","Aortic Aneurysm","Mitral Disease","AORTIC VALVE DISEASES","Aortic Dissection","2026-05-11",{"date":211,"type":42},"2026-05-14",{"date":213,"type":22},"2026-05-31",{"date":215,"type":22},"2027-05-30",{"name":217,"class":49},"Shih,Wen-Chi",{"id":219,"slug":220,"hasResults":12,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":12,"sex":17,"minAge":225,"maxAge":59,"enrollmentInfo":226,"targetDuration":4,"studyType":23,"phases":228,"briefSummary":229,"conditions":230,"keywords":244,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":258,"locationsCount":84},"100592604","dietary-supplements-in-patients-with-coronary-artery-bypass-grafting-for-improving-the-quality-of-healthcare-delivery-100592604","NCT06995586","Dietary Supplements in Patients With Coronary Artery Bypass Grafting for Improving the Quality of Healthcare Delivery.","The Synergistic Action of Vitamins and Dietary Supplements in Patients With Coronary Artery Bypass Grafting for Improving the Quality of Healthcare Delivery.","Inclusion Criteria:\n\n* The subjects will be people 40-80 years old, with coronary artery disease, and mental clarity who will undergo Coronary Aortic Bypass (CABG) in our clinic (Public Cardiothoracic Surgery clinic in Nicosia General Hospital) and will be randomized into 2 groups (intervention group and control group).\n* Signed consent form\n* Ability to adhere to the protocol\n\nExclusion Criteria:\n\n* Any psychiatric, neurological or motor disorder.\n* Hypersensitivity to the components of the supplement.\n* Combined Cardiac Surgery other than CABG and valve or aortic\n* Concurrent participation in other clinical trials.\n* Previous use of any probiotics, prebiotics, adsorbent dietary supplements, Vitamin C and\u002For Omega 3 fatty acids.","40 Years",{"count":227,"type":22},108,[25],"Cardiovascular disease (CVD) remains the leading cause of death worldwide. Prevention of CAD by targeting modifiable factors remains a key public health priority. L-Ascorbic Acid (Vitamin C - Vit. C) and Omega 3 fatty acids, Eicosapentaenoic \u002F Docosahexaenoic Acid (EPO\u002FDHA), powerful but also necessary antioxidants for the human body, after observational studies as well as randomized studies seem to have a beneficial effect in the direction of the prevention of CVD with pleiotropic mechanisms. Lignin, a polymer of plant origin that is considered a dietary fiber, has a developed porous structure and can retain exogenous and endogenous toxins, and pathogenic microorganisms. Lactulose considered a prebiotic provides a selective substrate for the metabolism of saccharolytic bacteria with bifidogenic activity and multiple benefits to the host's gut health. Coronary artery bypass grafting (CABG) is an established surgical intervention and treatment of symptoms of myocardial ischemia that improves patient survival Optimal Medical Therapy (OMT) after coronary arterial bypass grafting (CABG) as described in current clinical practice could be made even better by the addition of these beneficial food supplements.\n\nA randomized controlled trial is proposed in an intervention group of 54 post-CABG patients who will be given daily orally in addition to the usual medication, 1000 mg Vitamin C, 840 mg EPO\u002FDHA, 2130 mg Lignin \\& 720 mg Lactulose and a control group of 54 patients (Control Group) in which only usual medication will be administered. The intervention will take place from the 15th postoperative day when CAGB patients are discharged and lasts for 2.5 months (10 weeks) postoperatively. The data will be collected on the 15th, 80-90th postop day in 6 months and 12 months postop and then the statistical analysis of the data will be performed. Considering the number of CABG surgeries performed electively in our clinic, this study is expected to be completed in approximately 2-3 years from the day of initiation.\n\nThe expected knowledge through the expected results such as these will emerge from this study is the potentially beneficial effect of our food supplements administration (intervention), i.e. Vitamin C, EPO\u002FDHA, Lignin \\& Lactulose, on the postoperative course of our patients. Some degree of improvement in the well-being and clinical picture of our patients postoperatively is expected, which will be thoroughly investigated in each phase of the study.",[231,232,233,234,235,236,237,238,239,240,241,31,242,243],"Cardio-pulmonary Bypass","Cardiovascular Diseases","Omega-3 Polyunsaturated Fatty Acids","Omega-3 Supplementation","Vitamin C","Supplements","Postoperative Depression","Antioxidants","Lactulose","Postoperative","Optimal Medical Therapy","Coronary Artery Bypass Grafting","Prebiotics",[231,232,245,235,238,239,246,236,247,241,31,242,248,249,250,251],"Omega-3 polyunsaturated fatty acids","Omega-3 supplementation","postoperative","postoperative depression","Lignin","adsorbent","prebiotics","2026-05-09",{"date":254,"type":42},"2026-05-13",{"date":256,"type":22},"2026-09-01",{"date":187,"type":22},{"name":259,"class":49},"Nicosia General Hospital",{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":23,"phases":270,"briefSummary":271,"conditions":272,"keywords":279,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":84},"100613651","surgical-versus-percutaneous-revascularization-in-patients-with-reduced-left-ventricular-function-stich-30-nl-100613651","NCT07269366","Surgical Versus Percutaneous Revascularization in Patients With Reduced Left Ventricular Function (STICH 3.0-NL)","Surgical Versus Percutaneous Revascularization in Patients With Reduced Left Ventricular Function","STICH 3*0-NL","Inclusion Criteria:\n\n* Age ≥ 18 years\n* LVEF≤ 40%\n* Angina pectoris, CCS≥2 and\u002For hospitalization for ACS or heart failure within 1 year prior to randomization\n* Multivessel CAD (2-3 vessel-disease with coronary lesions \\>70% and involvement of proximal LAD, and\u002For LM stenosis of \\>50%). Target vessels are determined by the local Heart Time\n* Clinical and angiographical characteristics suitable for isolated coronary revascularization both by CABG or PCI according to the judgment of the local Heart Team\n* Written informed consent\n\nExclusion Criteria:\n\n* ACS \\\u003C 48 hours before randomization\n* Valvular\u002Fstructural heart disease requiring intervention\n* Contra-indications to DAPT\n* Non-cardiac condition with life expectancy \\\u003C 1 year\n* Previous CABG\n* Decompensated HF at the time of inclusion",{"count":269,"type":22},358,[25],"This randomized multicenter trial compares coronary artery bypass grafting (CABG) with percutaneous coronary intervention (PCI) in 358 patients with ischemic left ventricular dysfunction and multivessel coronary disease. The study evaluates differences in survival, major cardiovascular events, and quality of life over 4 years, and contributes to the international STICH 3.0 collaboration assessing long-term outcomes.",[173,273,274,31,275,276,277,278],"Coronary Artery Disease (CAD)","Multivessel Coronary Artery Disease","CABG in Low EF","Heart Failure","PCI","Revascularization",[280,281,282,283,284,285,286,287,288],"coronary artery","coronary artery disease","heart failure","low ejection fraction","hfref","cabg","coronary artery bypass graft","pci","revascularization","2026-05-07",{"date":291,"type":42},"2026-05-12",{"date":293,"type":22},"2026-05",{"date":295,"type":22},"2034-05",{"name":297,"class":49},"University Medical Center Groningen",{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":12,"sex":17,"minAge":225,"maxAge":305,"enrollmentInfo":306,"targetDuration":4,"studyType":23,"phases":308,"briefSummary":309,"conditions":310,"keywords":311,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":323,"locationsCount":84},"100637281","comparative-effects-of-elliptical-exercises-and-swiss-ball-aerobics-exercises-in-post-cabg-patients-100637281","NCT07578805","Comparative Effects of Elliptical Exercises and Swiss Ball Aerobics Exercises in Post CABG Patients","Comparative Effects Of Elliptical Exercises And Swiss Ball Aerobics Exercises On Functional Capacity, Heart Rate, Dyspnea , And Quality Of Life In Post CABG Patients","INCLUSION CRITERIA\n\n* Adult patients aged 40 to 60 years who have undergone elective or scheduled coronary artery bypass grafting (CABG) surgery.\n* Post-operative duration between 2 to 6 weeks, medically cleared to begin rehabilitation exercises.\n* Hemodynamically stable (normal vital signs, no signs of acute cardiac distress).\n* Willing and able to participate in a supervised rehabilitation program.\n\nEXCLUSION CRITERIA\n\n* Patients with unstable angina, recent myocardial infarction (\\\u003C2 weeks), or uncontrolled arrhythmias.\n* Patients with severe valvular heart disease or left ventricular ejection fraction \\\u003C30%.\n* Individuals with neurological conditions (e.g., Parkinson's disease, stroke) that impair mobility or coordination.\n* Patients with severe musculoskeletal disorders (e.g., joint replacement, severe arthritis, recent fractures).\n* Cognitive impairment (e.g., dementia, significant memory loss) that prevents understanding or following instructions.","60 Years",{"count":307,"type":22},32,[25],"This randomized controlled trial will compare the effectiveness of elliptical exercise training and Swiss ball exercise therapy in post-CABG patients. A total of 32 participants will be recruited through convenient sampling and randomly allocated into two groups (16 each). Group A will receive supervised elliptical exercise training, while Group B will perform Swiss ball exercises, with sessions conducted three times per week for 6-8 weeks. Outcomes including functional exercise capacity (Six-Minute Walk Test), resting heart rate (pulse oximetry), dyspnea (Modified Borg Scale), and quality of life (SF-36) will be assessed at baseline and post-intervention. Data will be analyzed using SPSS to determine the more effective rehabilitation approach for improving recovery after CABG.",[31],[312,313,314,315,316,317],"CABG,","dyspnea,","elliptical exercises,","functional capacity,","quality of life,","Swiss ball exercises","2026-05-05",{"date":209,"type":42},{"date":321,"type":22},"2026-05-10",{"date":41,"type":22},{"name":324,"class":49},"Riphah International University",{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":31,"eligibilityCriteria":331,"healthyVolunteers":12,"sex":17,"minAge":332,"maxAge":333,"enrollmentInfo":334,"targetDuration":4,"studyType":23,"phases":336,"briefSummary":337,"conditions":338,"keywords":339,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":345,"completionDateStruct":346,"leadSponsor":348,"locationsCount":4},"100637484","effects-of-e-care-protocol-in-patients-with-coronary-artery-bypass-graft-100637484","NCT07574411","Effects of E-care Protocol in Patients With Coronary Artery Bypass Graft","Effects of E-care Protocol in Length of Hospital Stay and Respiratory Failure in Patients With Coronary Artery Bypass Graft","Inclusion Criteria:\n\n* Male and female of \\>45 years diagnosed with CAD and are undergone Coronary Artery Bypass Graft with stable circulation.\n* Stable vitals.\n* With normal cognition and being able to cooperate with the CR training.\n* Agreed to participate in the trial and signed the consent for .\n\nExclusion Criteria:\n\n* Pregnant\n* Undergoing aortic surgery or equivalent surgery within 6 months\n* History of cardiogenic shock or sudden cardiac arrest and severe hypertension\n* Having complications with persistent ischemia, hemodynamic impairment, or at risk of arterial occlusion with massive myocardial infarction\n* Having complications with unstable angina, malignant arrhythmia","45 Years","70 Years",{"count":335,"type":22},42,[25],"Coronary artery disease (CAD) is a heart disease caused by the buildup of plaque inside the coronary arteries that restricts blood flow to the heart which leads to heart attack. If it involve more than one artery it will be more critical so the preferred treatment will be coronary artery bypass graft. Respiratory failure after Coronary Artery Bypass Grafting (CABG) is a serious complication with multifactorial causes i.e. pneumonia and atelectasis in inpatients.\n\nPostoperative pulmonary complications will be diagnosed using the Melbourne Group Scale (MGS), applied daily from postoperative day 1 to day 7. A score of ≥4 positive criteria will be used to identify PPCs. The scale's criteria will include chest radiograph findings, oxygen saturation, sputum characteristics, inflammatory markers, and ventilation data, physician diagnosis of pneumonia, readmission to ICU for respiratory reasons, prolong ventilation\\> 24 hours, unplanned use of non-invasive ventilation.",[31],[340,31,341,342],"CAD","E CARE protocol","RESPIRATORY FAILURE","2026-05-04",{"date":289,"type":42},{"date":321,"type":22},{"date":347,"type":22},"2026-08-02",{"name":324,"class":49},{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":4,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":356,"targetDuration":4,"studyType":23,"phases":358,"briefSummary":359,"conditions":360,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":366,"leadSponsor":368,"locationsCount":84},"100636718","low-dose-colchicine-for-cabg-graft-failure-prevention-100636718","NCT07569328","Low-dose Colchicine for CABG Graft Failure Prevention","Low-dose Colchicine for CABG Graft Failure Prevention: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. Be male or female, aged 18 years or older;\n2. Within 3 days after successful isolated coronary artery bypass grafting (CABG);\n3. Sign informed consent;\n\nExclusion Criteria:\n\n1. Severe valvular heart disease requiring concomitant or staged valvular surgery;\n2. History of non-skin cancer in the past 3 years;\n3. Inflammatory bowel disease or chronic diarrhea;\n4. Neuromuscular diseases or non-transient creatine kinase levels greater than 3 times the upper limit of the normal range (except those associated with myocardial infarction);\n5. Clinically significant non-transient (At least 2 laboratory tests) blood abnormalities (Hemoglobin \\\u003C100g\u002FL or hematocrit \\\u003C 30% or \\> 52% or white blood cell count \\\u003C 3×109\u002FL or platelet count \\\u003C 100×109\u002FL);\n6. Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m² (based on the CKDEPI formula);\n7. Serum alanine aminotransferase and\u002For aspartate aminotransferase levels greater than 2 times the upper limit of the normal range, accompanied by serum total bilirubin levels greater than 2 times the upper limit of the normal range or severe liver disease with coagulation disorders (INR\\>1.5) (except for elevated glutamic oxalacetic transaminase associated with myocardial infarction);\n8. Decline in cognitive function due to inability to perform basic activities of daily living independently;\n9. Drug or alcohol abuse;\n10. Other immunosuppressive therapies already in existence or planned;\n11. Other causes require long-term colchicine treatment;\n12. History of clear or suspected colchicine allergy;\n13. Strong CYP3A4 or P-glycoprotein inhibitors (such as cyclosporine, antiretrovirals, antifungals, erythromycin and clarithromycin) have been used and no other alternative drugs can be used.",{"count":357,"type":22},622,[25],"This study aims to evaluate whether daily low-dose colchicine (0.5 mg), administered in addition to the standard secondary prevention regimen recommended in clinical guidelines after coronary artery bypass grafting (CABG), can further prevent graft failure after CABG through a prospective, randomized, double-blind, placebo-controlled clinical trial.",[202,31,361],"Colchicine","2026-04-29",{"date":364,"type":42},"2026-05-06",{"date":256,"type":22},{"date":367,"type":22},"2029-09-01",{"name":369,"class":49},"Beijing Anzhen Hospital",{"id":371,"slug":372,"hasResults":12,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":376,"eligibilityCriteria":377,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":23,"phases":380,"briefSummary":381,"conditions":382,"keywords":387,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":84},"100630289","the-relationship-between-blood-flow-readings-during-surgery-and-how-well-the-graft-stays-open-and-how-patients-recover-afterward-in-coronary-artery-bypass-graft-surgery-100630289","NCT07485738","The Relationship Between Blood Flow Readings During Surgery and How Well the Graft Stays Open and How Patients Recover Afterward in Coronary Artery Bypass Graft Surgery","Surgical Measurement for Accurate Revascularization Using Transit-time FLOW (SMARTFLOW):Patency","SMARTFLOW","Inclusion Criteria:\n\n1. Age \\>18 years\n2. First-time, non-emergent isolated multivessel CABG through median sternotomy\n3. Willing and able to provide written informed consent and comply with all study procedures, including QOL questionnaires\n\nExclusion Criteria:\n\n1. Reoperation\n2. Emergency procedures\n3. Combined CABG + other cardiac or non-cardiac surgery\n4. Isolated single vessel CABG\n5. Minimally invasive CABG\n6. Inability to undergo coronary computed tomographic angiography (CCTA)\n7. Unable to provide written informed consent or comply with all the study procedures.",{"count":379,"type":22},1242,[25],"The purpose of this study is to learn more about a tool called Transit-Time Flow Measurement (TTFM). TTFM uses sound waves during surgery to check how well blood is flowing through blood vessels. This helps doctors see if the blood flow is good during coronary artery bypass grafting (CABG), which is a type of heart surgery",[383,31,384,385,386],"CABG Graft Integrity","Blood Flow","Transit-time Flow Measurement","Heart Disease",[376],"2026-04-20",{"date":390,"type":42},"2026-04-22",{"date":392,"type":42},"2026-03-30",{"date":394,"type":22},"2032-03",{"name":396,"class":49},"Weill Medical College of Cornell University",{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":401,"acronym":402,"eligibilityCriteria":403,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":404,"targetDuration":4,"studyType":406,"phases":4,"briefSummary":407,"conditions":408,"keywords":410,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":4},"100630703","the-cdac-study---cerebral-dysfunction-after-coronary-revascularization-100630703","NCT07491120","The CDAC Study - Cerebral Dysfunction After Coronary Revascularization","CDAC","Inclusion Criteria:\n\n* Criteria for enrollment are age 18 years or more.\n* A candidate for either elective single or multi-vessel CABG or PCI without limits for lesion location, lesion characteristics or complexity, the number of vessels treated, or the number of stents or bypass grafts placed, or the type of bypass grafts.\n* The decision to undergo either CABG or PCI will be made by the treating physician and patient before research study enrollment, and thus, the revascularization decision is not directed by this research protocol.\n\nExclusion Criteria:\n\nPatients will not be enrolled due to:\n\n* Concomitant valve therapy (surgical or transcatheter).\n* Prior CABG or surgical valve repair\u002Freplacement surgery.\n* PCI within 1 year of the study entry procedure.\n* A hybrid revascularization procedure (PCI plus CABG), an untreated carotid artery stenosis of \\>70%, inability to provide informed consent.\n* The inability to perform pre-procedure tablet-based neurocognitive testing.\n* The lack of stated agreement to return for follow-up on-site neurocognitive testing at the prescribed time points.",{"count":405,"type":22},600,"OBSERVATIONAL","Neurocognitive decline has long been suspected to be a potential long-term complication of coronary artery bypass grafting surgery (CABG), with reports of post-operative cognitive dysfunction by objective testing approaching 15-50% of patients in the year following surgery. To determine the true rate of long-term cognitive dysfunction following CABG compared to percutaneous coronary intervention (PCI or coronary stent placement), we propose a multi-center, two-group, non-randomized study using computer-based customized neurocognitive testing (Cogsate), prior to the procedure and then at 30 days, 1-year and 2-years after revascularization to evaluate cognitive function vital for the maintenance and advancement of professional and personal activities. It is anticipated that the study will document a higher rate of cognitive dysfunction in the CABG group, that the landmark study will provide both the patient and physician with the information necessary to make an informed decision regarding the cognitive risks of CABG versus PCI when faced with the need for coronary revascularization, and that these results will change the clinical practice of recommending CABG as a primary revascularization option for those wishing to preserve cognitive function.",[31,277,409],"Cognitive Decline",[31,277,409],"2026-03-19",{"date":413,"type":42},"2026-03-24",{"date":415,"type":22},"2027-01-01",{"date":417,"type":22},"2033-01-01",{"name":419,"class":49},"The Scripps Research Institute",{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":426,"eligibilityCriteria":427,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":428,"targetDuration":4,"studyType":406,"phases":4,"briefSummary":430,"conditions":431,"keywords":432,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":84},"100629918","risk-stratification-of-mace-in-heart-failure-patients-who-undergoing-cabg-100629918","NCT07480915","Risk Stratification of MACE in Heart Failure Patients Who Undergoing CABG","Risk Stratification of MACE Based on GDF-15 in Heart Failure Patients Who Undergoing Coronary Artery Bypass Grafting: an Observational Multicenter Prospective Study","PROFILE-HF","Inclusion Criteria:\n\n* Heart Failure\n* Planned coronary artery bypass grafting\n\nExclusion Criteria:\n\n* Myocardial infarction\n* Stroke\n* Presence of implanted devices;\n* Need for additional cardiac surgery other than coronary artery bypass grafting (valve repair, aneurysm);\n* Severe renal dysfunction (GFR \\\u003C30 ml\u002Fmin\u002F1.73 m2);\n* Severe comorbidities: active cancer; infiltrative cardiac diseases (sarcoidosis, amyloidosis, storage diseases); autoimmune diseases; acute infectious diseases and exacerbations of chronic somatic diseases.",{"count":429,"type":22},160,"PROFILE-HF is a multicenter, observational, prospective study of the clinical course and outcomes of chronic heart failure (HF) and coronary artery disease (CAD) in patients undergoing coronary artery bypass grafting (CABG).\n\nThe objective of the study is to develop a method for assessing the risk of adverse cardiovascular events in patients with CAD and HF who have undergone CABG, based on preoperative GDF-15 concentrations.\n\nThe study will have a 12-month follow-up period; one in-person visit is planned at the end of the follow-up period. If it is not possible to visit a doctor in person, information will be collected through telephone contact with the patient or his relative or person caring for the patient.",[276,202,31],[276,173,31,242,433,434,435],"GDF-15","Growth differentiation factor - 15","Prognosis","2026-03-13",{"date":438,"type":42},"2026-03-18",{"date":440,"type":42},"2026-03-04",{"date":442,"type":22},"2028-03",{"name":444,"class":49},"Tomsk National Research Medical Center of the Russian Academy of Sciences",{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":452,"targetDuration":4,"studyType":406,"phases":4,"briefSummary":453,"conditions":454,"keywords":457,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":465,"locationsCount":4},"100628922","impact-of-visceral-adiposity-on-postoperative-atrial-fibrillation-after-cabg-100628922","NCT07467941","Impact of Visceral Adiposity on Postoperative Atrial Fibrillation After CABG","Impact of Visceral Adiposity on Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting (CABG): A Prospective Observational Study","Inclusion Criteria:\n\n* Elective isolated coronary artery bypass graft surgery (on-pump)\n* Age ≥18 years, planned prospectively in 300 patients\n\nExclusion Criteria:\n\n* Patients requiring urgent or emergency surgery\n* Off-pump coronary artery bypass graft surgery\n* Surgeries other than isolated coronary artery bypass graft\n* Patients in whom abdominal ultrasound measurement cannot be performed (e.g., due to severe deformity, wounds, edema)\n* Active malignancy\n* eGFR \\\u003C30 mL\u002Fmin\n* Advanced-stage chronic obstructive pulmonary disease (COPD)\n* Preoperative atrial fibrillation or atrial flutter\n* Patients who do not provide written informed consent for the study",{"count":94,"type":22},"Obesity has become a major public health problem in both developed and developing countries, with a continuous increase particularly since the 1980s. Moreover, it is a well-established metabolic risk factor for diabetes mellitus, hypertension, and various types of cancer, as well as cardiovascular diseases such as heart failure and coronary artery disease. Body mass index (BMI) is calculated by dividing body weight in kilograms by the square of height in meters and is widely used as an indicator of obesity. However, BMI does not quantitatively reflect body fat distribution and fails to account for components such as skeletal muscle and bone mass. Therefore, interest in assessing body fat distribution has increased, and in recent years, studies evaluating the correlation between anthropometric, biochemical, and anatomical measurements and clinical outcomes have become more frequent. In particular, it is acknowledged that abdominal obesity cannot be accurately represented by BMI alone and is primarily associated with visceral adipose tissue (VAT). The aim of this study is to evaluate the association between preoperative visceral and subcutaneous adipose tissue measurements (VAT and SAT), assessed by ultrasonography in patients scheduled for open-heart surgery, and the development of postoperative atrial fibrillation.",[31,455,456],"Visceral Adipose Tissue","Atrial Fibrillation (AF)",[456,455,31],"2026-03-08",{"date":460,"type":42},"2026-03-12",{"date":462,"type":22},"2026-04-01",{"date":464,"type":22},"2027-01-22",{"name":466,"class":467},"Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital","OTHER_GOV",{"id":469,"slug":470,"hasResults":12,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":474,"eligibilityCriteria":475,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":476,"enrollmentInfo":477,"targetDuration":4,"studyType":23,"phases":478,"briefSummary":479,"conditions":480,"keywords":482,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":84},"100627660","comparative-analysis-of-analgesic-approaches-in-the-early-period-after-cabg-100627660","NCT07451522","Comparative Analysis of Analgesic Approaches in the Early Period After CABG","Comparative Characteristics of Analgesia Methods in the Early Postoperative Period After Coronary Artery Bypass Grafting (CABG)","CABG-PAIN","Inclusion Criteria:\n\n* ASA score less then 3, Signed inform consent, Absence of preoperative drugs administration that affects patient's perception of pain, No active infection process, BMI index \\>18,5 kg\\\\m2 and \\\u003C 35 kg\u002Fm2, CABG, Age 18-75 years\n\nExclusion Criteria (the presence of at least one is sufficient):\n\n* Failure to meet the inclusion criteria.\n* High severity according to ASA (class IV or higher), which is associated with a high probability of prolonged mechanical ventilation, hemodynamic instability, and inability to use drugs affecting cardiac output and\u002For total peripheral vascular resistance.\n* Contraindications to the use of tafalgin and\u002For morphine in accordance with the approved Summary of Product Characteristics (hypersensitivity to tafalgin, morphine, other opioids, or any excipients).\n* Pregnancy or lactation.\n* Acute or prolonged chronic intoxication with drugs or substances depressing the central nervous system (alcohol, barbiturates, opioid drugs, benzodiazepines).\n* Use of monoamine oxidase inhibitors (MAOIs) or less than 14 days since their discontinuation.\n* Liver cirrhosis, Child-Pugh class C.\n* Acute renal failure requiring renal replacement therapy.\n* Unresected malignant neoplasm.\n* Mesenteric thrombosis or another severe abdominal pain syndrome of unclear etiology at the time of inclusion.\n* Simultaneous participation in another clinical study.\n* Marked CNS depression due to any cause, except for acute poisoning.\n* COPD stage III and\u002For bronchial asthma in the exacerbation phase.\n* Any clinically significant condition, disease, or circumstance in the medical history that, in the opinion of the investigator, precludes participation in the study.\n* Psychiatric, physical, or other conditions preventing adequate assessment of the patient's behavior or proper compliance with the study protocol.\n* Postoperative hemodynamic instability requiring high-dose inotropic and\u002For vasopressor support (epinephrine \\> 0.1 μg\u002Fkg\u002Fmin, dopamine \\> 10 μg\u002Fkg\u002Fmin, norepinephrine \\> 0.2 μg\u002Fkg\u002Fmin) and\u002For mechanical circulatory support.\n* Refusal to participate in the study.","75 Years",{"count":120,"type":22},[25],"The goal of this clinical trial is to study postoperative analgesia in patients undergoing CABG. And learn if tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amid) treats pain not inferiory then morphine. The main questions it aims to answer are:\n\nDoes tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amid) lower the VAS score same way as a morphine? What medical problems do participants have when taking tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amid)?\n\nParticipants will:\n\nGroup (1)- subcutaneous single dose of morphine 10 mg would be administred based on VAS score \\> 3 during 24 hours after CABG.\n\nExprimental group (2)- subcutaneous single dose of tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amid) - 0.4 mg would be administred based on VAS score \\> 3 during 24 hours after CABG.\n\nEfficacy was assessed using the VAS scale decreassion. Hemodynamic parameters and arterial blood gases were also assessed.",[202,31,481],"Analgesia Assessment",[31,340,483,484,485],"Morphine","Tafalgin","VAS","2026-02-28",{"date":488,"type":42},"2026-03-05",{"date":490,"type":42},"2025-12-01",{"date":492,"type":22},"2026-03-15",{"name":494,"class":467},"Primorsky Regional General Hospital #1",{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":501,"eligibilityCriteria":502,"healthyVolunteers":503,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":504,"targetDuration":4,"studyType":23,"phases":506,"briefSummary":507,"conditions":508,"keywords":519,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":530,"locationsCount":160},"100562499","prevention-of-edema-after-coronary-artery-bypass-graft-by-customized-pressure-guided-elastic-bandages-100562499","NCT06603961","Prevention of Edema After Coronary Artery Bypass Graft by Customized Pressure-guided Elastic Bandages","Efficacy of Customized Pressure-Guided Elastic Bandages in Preventing Postoperative Edema and Complications in Coronary Artery Bypass Graft (CABG) Patients: A Comparative Study of Compression Therapy and Standard Post-CABG Care.","PEACCE","Inclusion Criteria:\n\n1. All patients scheduled for elective coronary artery bypass grafting (CABG) surgery with saphenous vein harvesting from the leg at Siriraj Hospital.\n2. Patients aged 18 years and older undergoing CABG surgery with saphenous vein harvesting from the leg at Siriraj Hospital, who willingly consent to participate in the study.\n\nExclusion Criteria:\n\n1. Patients with an Ankle-brachial pressure index (ABI) \\\u003C 0.8\n2. Patients with severe leg swelling (pitting edema of grade 3 or higher) or with pre-existing or post-operative heart failure that remains uncontrolled despite diuretic therapy.\n3. Patients with occlusive peripheral arterial disease (PAD) or chronic venous insufficiency (CEAP 2s), characterized by significant venous stasis, leg pain, varicose veins, or lymphadenopathy.",true,{"count":505,"type":22},106,[25],"The study aimed to assess the efficacy of customized pressure-guided elastic bandages (CPG-EB) in preventing postoperative edema and complications in Coronary Artery Bypass Graft (CABG) patients. While compression therapy, like compressive stockings, has benefits in preventing edema, concerns about affordability persist. CPG-EB provides optimal sub-bandage pressure, proven effective in venous leg ulcers. Implementing CPG-EB post-CABG could enhance venous blood flow, reducing complications and improving outcomes. Patients were divided into two groups: one with CPG-EB and the other standard post-CABG care. Data collected at 1, 2, and 6 weeks post-surgery assessed swelling and wound complications. Comparative analysis used standardized criteria.",[509,510,511,512,513,31,514,515,516,517,518],"Limb Edema","Surgical Site Infections","Leg Swelling","Compression Bandages","Coronary Artery Bypass Graft","Saphenectomy","Saphenous Vein","Delayed Wound Healing","Post Operative Complications","Post Operative Surgical Site Infection",[520,521,522,31,523],"compression bandages","compression therapy","customized pressure-guided elastic bandages","coronary arterial bypass graft","2026-02-06",{"date":526,"type":42},"2026-02-09",{"date":528,"type":42},"2025-01-19",{"date":213,"type":22},{"name":531,"class":49},"Siriraj Hospital",{"id":533,"slug":534,"hasResults":12,"nctId":535,"briefTitle":536,"officialTitle":536,"acronym":4,"eligibilityCriteria":537,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":118,"enrollmentInfo":538,"targetDuration":4,"studyType":23,"phases":539,"briefSummary":540,"conditions":541,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":552,"locationsCount":4},"100620646","role-of-opioid-free-anaesthesia-in-elderly-patients-undergoing-elective-coronary-artery-bypass-graft-surgeries-with-cardiopulmonary-bypass-in-enhanced-recovery-after-surgeries-100620646","NCT07360327","Role of Opioid Free Anaesthesia in Elderly Patients Undergoing Elective Coronary Artery Bypass Graft Surgeries With Cardiopulmonary Bypass in Enhanced Recovery After Surgeries","Inclusion Criteria:\n\n* Age group: above 65 years old of both sex. Undergoing an elective coronary artery bypass graft surgeries with cardiopulmonary bypass.\n\nExclusion Criteria:\n\n* Past or ongoing history of drug abuse.\n* Psychiatric disease and cognitive disorders.\n* Inability to perform the confusion assessment method for the intensive care unit (CAM-ICU) test.\n* EF\\\u003C40 %.\n* 1st or 2nd degree Heart block.\n* HR \\\u003C50 bpm.\n* Allergy from drugs used in this study.\n* Use of a left ventricular assist device, IAB or ECMO pri",{"count":142,"type":22},[25],"The introduction of synthetic opioids in 1960 to general anesthesia together with sedative hypnotics and muscle relaxants allowed the appearance of the concept of multimodal balanced anesthesia. Although they help in achieving hemodynamic stability during anesthesia of open heart surgeries, their administration consequences are neither scarce nor benign to the patient. Perioperative opioids are associated with increased incidence of respiratory depression, prolonged mechanical ventilation, nausea and vomiting, prolonged sedation, Postoperative ileus (POI), urine retention, Postoperative cognitive dysfunction (POCD), immune depression and hyperalgesia (Beloeil et al., 2018).\n\nCoronary artery bypass graft surgery with cardiopulmonary bypass (CPB) is particularly vulnerable to the above-mentioned complications. Indeed, some of the side effects of this surgery overlap with the adverse effects of opioids. Postoperative pulmonary complications are observed in up to 50% of patients (Fisscher et al., 2022) and POCD or delirium in 4-54% according to studies (Bhushan et al., 2021). Whereas major gastrointestinal complications are estimated to occur in around 3% of patients, essentially acute pancreatitis, postoperative ileus (Marsoner et al., 2019).\n\nOpioid-free anesthesia (OFA) strategies have emerged to avoid intraoperative opioid use. It is based on the fact that a sympathetic reaction evidenced by hemodynamic changes in an anesthetised patient does not systematically reflect pain. In addition, a sleeping patient will not recall pain, while hormonal stress and sympathetic and inflammatory reactions can be controlled by therapeutic classes",[31,542,543,544,545],"Dexmedetomidine","Ketamine","Opioid Free Anesthesia","Opioid Based Anesthesia","2026-01-14",{"date":548,"type":42},"2026-01-22",{"date":550,"type":22},"2026-01-01",{"date":44,"type":22},{"name":553,"class":49},"Ain Shams University",{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":4,"eligibilityCriteria":560,"healthyVolunteers":12,"sex":17,"minAge":561,"maxAge":305,"enrollmentInfo":562,"targetDuration":4,"studyType":23,"phases":564,"briefSummary":565,"conditions":566,"keywords":567,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":578,"completionDateStruct":580,"leadSponsor":582,"locationsCount":84},"100618433","multimodal-vr-rehabilitation-for-cardiorespiratory-fitness-in-cabg-phase-ii-100618433","NCT07331558","Multimodal VR Rehabilitation for Cardiorespiratory Fitness in CABG Phase II","Effects of Multimodal Virtual Reality-based Rehabilitation on Dyspnea, Cardiorespiratory Fitness, Left Ventricular Ejection Fraction, and Quality of Life in CABG Phase II","Inclusion Criteria:\n\n* Patients who underwent CABG surgery will be recruited after twelve weeks\n* Both male and female\n* Age 30-60 years old\n* LVEF of \\\u003C 40%\n* Persistent dyspnea with a self-rated intensity of ⩾5 (out of 10) on a visual analogue dyspnea scale (this dyspnea rating was only used as an inclusion criterion and not as a measure for outcome)\n* Preserved cognitive function (Montreal Cognitive Assessment score \\>24)\n\nExclusion Criteria:\n\n* Patient with recurrent history of CABG\n* Had a non-cardiac surgical procedure ≤2 months prior to recruitment\n* Unstable angina, uncontrolled hypertension (blood pressure \\>180\u002F100 mmHg), a pacemaker or atrial fibrillation, documented peak orifice area valve stenosis, symptomatic peripheral arterial disease that limits exercise capacity.\n* Documented chronic obstructive pulmonary disease (FEV1 \\\u003C60% and FVC \\\u003C60%)\n* Any shoulder impairment that would limit exercise participation\n* Patients with Kinesiophobia\n* Epilepsy, vertigo, eyesight impairment (conditions contraindicated for VR)","30 Years",{"count":563,"type":22},66,[25],"It will be a randomized clinical trial with a sample size of 66. A convenient sampling technique will be used to recruit the CABG phase II patients for the study. Then, they will be divided into three groups by block randomization. Weight-bearing Liuzijue Qigong will be given as a baseline treatment to all groups. In group A, patients will engage in multimodal circuit training while simultaneously viewing the nature scenes through VR in a clinical setting, in group B, patients will be given multimodal circuit training in a clinical setting while in group C, patients will be given multimodal circuit training through telerehabilitation. The dyspnea 12 Questionnaire will be used for measuring dyspnea, Cooper's 12-minute test will be used to assess cardiorespiratory fitness, echocardiography will be used to assess Left ventricular ejection fraction, EQ-5D-5L will be used to assess quality of life, and Pittsburgh Sleep Quality Index (PSQI) will be used to assess the quality of sleep. Data will be entered and analyzed through SPSS version 21.",[31],[568,569,570,571,572,573,574],"multimodal treatment","virtual reality","telerehabilitation","education","Circuit Based Exercise","diet","psychological well-being","2025-12-29",{"date":577,"type":42},"2026-01-12",{"date":579,"type":42},"2025-12-02",{"date":581,"type":22},"2026-02-25",{"name":324,"class":49},{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":589,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":591,"targetDuration":4,"studyType":23,"phases":592,"briefSummary":594,"conditions":595,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":600,"leadSponsor":602,"locationsCount":84},"100577794","phase-4-pilot-trial-of-colchicine-for-graft-failure-in-cabg-100577794","NCT06802926","Pilot Trial of Colchicine for Graft Failure in CABG","A Single Center Pilot Trial of Preliminary Effect of Colchicine on Graft Failure in Patients Underwent CABG","CoCAB-Pilot","Inclusion Criteria:\n\n* Age≥18 years old，\n* Any sex，\n* Signed informed consent，\n* Within 3 days after a successful isolated CABG\n\nExclusion Criteria:\n\n* Allergy,\n* Hematopoietic dysfunction,\n* Moderate to severe hepatic dysfunction,\n* Moderate to severe renal dysfunction.",{"count":120,"type":22},[593],"PHASE4","The goal of this pilot trial is to to evaluate the preliminary effect of oral colchicine therapy on graft outcomes in patients underwent primary isolated CABG.\n\nThe main questions it aims to answer is:\n\n1. Whether the oral colchicine therapy may reduce the failure outcome of grafts after CABG.\n2. Whether it is feasible to construct a muticenter powered trial to test the superiority hypothesis.\n\nResearchers will compare colchicine to none to see if colchicine works.\n\nParticipants will\n\n1. Take oral colchicine (0.5mg daily) therapy for 12 months after CABG.\n2. Clinical follow-up at Month 1, 6, and 12 after CABG.\n3. Protocol-driven CCTA at Week 1 and Month 12 after CABG.",[31,596,361],"Graft Failure",{"date":598,"type":42},"2026-01-02",{"date":575,"type":42},{"date":601,"type":22},"2028-12",{"name":603,"class":49},"Ruijin Hospital",{"id":605,"slug":606,"hasResults":12,"nctId":607,"briefTitle":608,"officialTitle":609,"acronym":610,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":612,"targetDuration":4,"studyType":23,"phases":614,"briefSummary":615,"conditions":616,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":619,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":625,"locationsCount":84},"100614792","clear-trial-ca330-cytokine-adsorption-column-for-anticoagulantantiplatelet-patients-in-non-elective-cpb-surgery-100614792","NCT07284199","CLEAR Trial: CA330 Cytokine Adsorption Column for Anticoagulant\u002FAntiplatelet Patients in Non-Elective CPB Surgery.","A Multicenter Randomized Controlled Trial of the CA330 Haemoadsorption Device in Patients for Limiting Excess Anticoagulation in Non-elective caRdiac Surgery With Cardiopulmonary Bypass","CLEAR","Inclusion Criteria:\n\n* Patients scheduled to undergo non-elective cardiovascular surgery requiring cardiopulmonary bypass;\n* Patients currently receiving one or more of the following medications - indobufen, ticagrelor, warfarin, cilostazol, dabigatran, rivaroxaban, or apixaban - with the last dose administered within the drug washout period.\n\nExclusion Criteria:\n\n* Patients with a history of chronic liver failure, stage 5 chronic kidney disease (CKD5), or requiring regular dialysis;\n* Patients in special physiological states: pregnancy or puerperium;\n* Patients with advanced-stage malignancy or scheduled cardiovascular surgery related to tumor management;\n* Patients with allergic reactions to cytokine adsorption column resin or related components;\n* Patients with known bleeding risk due to hematologic disorders such as heparin-induced thrombocytopenia, hemophilia, or acute sickle cell crisis;\n* Patients with severe infection, including severe sepsis.",{"count":613,"type":22},120,[25],"The goal of this clinical trial is to evaluate whether the CA330 cytokine adsorption column can reduce perioperative severe bleeding adverse events in patients receiving anticoagulant and\u002For antiplatelet therapy who undergo non-elective cardiac surgery with cardiopulmonary bypass.\n\nThe main questions it aims to answer are:\n\n* Does the use of the CA330 cytokine adsorption column lower the incidence of perioperative severe bleeding compared with standard care?\n* Does the intervention improve short-term clinical outcomes, such as transfusion requirements, reoperation rates for bleeding, or overall postoperative recovery?\n\nIf there is a comparison group: Researchers will compare patients treated with the CA330 cytokine adsorption column versus patients receiving standard cardiopulmonary bypass management to see if cytokine adsorption provides additional safety and efficacy benefits.\n\nParticipants will:\n\n* Undergo non-elective cardiac surgery requiring cardiopulmonary bypass.\n* Be randomly assigned to receive either the CA330 cytokine adsorption column integrated into the CPB circuit (intervention arm) or standard CPB management without the device (control arm).\n* Be monitored for perioperative bleeding outcomes, transfusion needs, reoperation rates, and overall postoperative prognosis.",[31,208,617],"Valvular Heart Diseases","2025-12-14",{"date":620,"type":42},"2025-12-16",{"date":622,"type":22},"2025-12-15",{"date":624,"type":22},"2028-06-30",{"name":369,"class":49},{"id":627,"slug":628,"hasResults":12,"nctId":629,"briefTitle":630,"officialTitle":631,"acronym":4,"eligibilityCriteria":632,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":633,"targetDuration":4,"studyType":406,"phases":4,"briefSummary":635,"conditions":636,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":637,"lastUpdatePostDateStruct":638,"startDateStruct":640,"completionDateStruct":642,"leadSponsor":643,"locationsCount":4},"100607918","drainage-technique-in-cabg-100607918","NCT07194798","Drainage Technique in CABG","A Prospective Randomized Trial Comparing the Posterior Pericardial Window Versus Retro-Cardiac Drain for the Prevention of Postoperative Atrial Fibrillation and Pericardial Complications Following CABG","Inclusion Criteria:\n\n* Adult patients (aged 18 and above) scheduled for elective, first-time coronary artery bypass grafting (CABG).\n* Patients with preserved left ventricular function (ejection fraction ≥ 35%).\n* Ability to provide informed consent and comply with follow-up protocols.\n* No prior history of atrial fibrillation or other significant arrhythmias.\n\nExclusion Criteria:\n\n* Patients undergoing combined cardiac procedures (e.g., valve repair or replacement).\n* Emergency CABG cases or re-operations.\n* Known bleeding disorders or ongoing anticoagulation therapy that cannot be paused.\n* Severe pericardial adhesions or anatomical abnormalities preventing safe creation of a posterior pericardial window.\n* Chronic pulmonary disease or pleural pathology that may interfere with drainage assessment.\n* Patients with active infections or systemic inflammatory conditions.",{"count":634,"type":22},122,"aims to compare the efficacy of the posterior pericardial window versus retro-cardiac drain in preventing postoperative atrial fibrillation and pericardial complications following CABG, while assessing their impact on hospital and ICU stay, pericardial effusions, re exploration for bleeding, post-operative blood transfusions, and mortality.",[31,456],"2025-09-19",{"date":639,"type":42},"2025-09-26",{"date":641,"type":22},"2025-10-01",{"date":44,"type":22},{"name":644,"class":49},"Assiut University",{"id":646,"slug":647,"hasResults":12,"nctId":648,"briefTitle":649,"officialTitle":650,"acronym":651,"eligibilityCriteria":652,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":653,"targetDuration":4,"studyType":406,"phases":4,"briefSummary":655,"conditions":656,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":637,"lastUpdatePostDateStruct":661,"startDateStruct":663,"completionDateStruct":665,"leadSponsor":667,"locationsCount":84},"100572879","ai-model-for-assessing-cardiac-surgeons-techniques-100572879","NCT06739005","AI Model for Assessing Cardiac Surgeons' Techniques","artifiCiAl Intelligence Model for Evaluating the Surgical Techniques of caRdiAc Surgeons (CAMERA)","CAMERA","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Undergoing internal mammary artery-to-left anterior descending artery bypass grafting\n* First-time recipient of isolated CABG surgery\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Patients with acute coronary syndrome\n* Patients with contraindications to coronary CT angiography or coronary angiography\n* Patients with renal insufficiency or active liver disease, including those with persistently elevated serum transaminases of unknown cause or any serum transaminase levels exceeding three times the upper limit of normal.",{"count":654,"type":22},284,"The goal of this study aims to investigate the use of artificial intelligence to analyze and evaluate the characteristics and proficiency of surgeons during vascular anastomosis in coronary artery bypass grafting (CABG) procedures. The main question it aims to answer is:\n\nConsistency assessment between AI evaluation scores and human expert evaluation scores for surgeons during left anterior descending (LAD) artery anastomosis.",[657,31,658,659,660],"CABG-patients","Cardiovascular Surgery","Surgeons","Artificial Intelligence (AI)",{"date":662,"type":42},"2025-09-23",{"date":664,"type":42},"2025-01-09",{"date":666,"type":22},"2027-07",{"name":668,"class":467},"China National Center for Cardiovascular Diseases",{"id":670,"slug":671,"hasResults":12,"nctId":672,"briefTitle":673,"officialTitle":673,"acronym":674,"eligibilityCriteria":675,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":676,"targetDuration":678,"studyType":406,"phases":4,"briefSummary":679,"conditions":680,"keywords":688,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":691,"lastUpdatePostDateStruct":692,"startDateStruct":694,"completionDateStruct":696,"leadSponsor":698,"locationsCount":84},"100600398","cardiac-rehabilitation-cohort-at-the-medicine-campus-davos-to-investigate-recovery-100600398","NCT07096973","Cardiac REhabilitation COhort at the Medicine Campus DaVos to invEstigate Recovery","RECOVER","Inclusion Criteria:\n\n* Patients undergoing CR at the HGK\n* Written informed consent\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Insufficient knowledge of the German language to understand study documents, the interview, or questionnaires interview without translation\n* Physical or psychological incapability to participate in the study",{"count":677,"type":22},10000,"10 Years","The RECOVER study, titled Cardiac Rehabilitation Cohort at the Medicine Campus Davos for Exploration of Recovery, is a prospective, non-interventional, monocentric cohort study conducted at the Hochgebirgsklinik Davos. The study is sponsored by Medicine Campus Davos AG and the Kühne Foundation, with an estimated start date in July 2025 and planned completion by December 2034, with the possibility of extension.\n\nThe principal investigator of the study is PD Dr. David Niederseer from Hochgebirgsklinik Davos, who also represents the study. The research team includes co-investigators such as Prof. Dr. Stefan Blankenberg and Prof. Dr. Andreas Ziegler from Cardio-CARE, Medicine Campus Davos, as well as Dr. Jan Vontobel from Hochgebirgsklinik Davos.\n\nThe study will enroll patients referred to Hochgebirgsklinik Davos for cardiac rehabilitation who provide informed consent. Cardiac rehabilitation is an evidence-based therapy for patients with heart disease, including those who have undergone cardiac procedures or surgeries.\n\nThe primary objectives are to evaluate baseline patient characteristics, rehabilitation strategies, predictors of recovery, and clinical outcomes during and after rehabilitation. To support this, a detailed database and biobank will be established to allow for comprehensive phenotyping, extensive clinical assessments, and long-term follow-up.\n\nRECOVER seeks to gain translational insights into how patient-specific factors - such as genetics, plasma, digital and clinical biomarkers, and comorbidities - influence long-term clinical outcomes. The goal is to identify modifiable risk factors to optimize individualized therapeutic approaches in cardiac rehabilitation.",[681,276,682,683,31,684,685,686,687],"Cardiac Rehabilitation","Cardiac Arrest (CA)","ACS (Acute Coronary Syndrome)","Valve Anomalies","LVAD (Left Ventricular Assist Device)","Heart Transplantation","Arrhythmia",[689,690],"cardiovascular diseases","cardiac rehabilitation","2025-09-11",{"date":693,"type":42},"2025-09-17",{"date":695,"type":42},"2025-08-05",{"date":697,"type":22},"2040-08-05",{"name":699,"class":49},"Hochgebirgsklinik Davos"]